Qrons (QRON) Accounts Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Qrons Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Qrons's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Qrons's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.11.

Qrons Accounts Receivable Historical Data

The historical data trend for Qrons's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons Accounts Receivable Chart

Qrons Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

Qrons Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Qrons Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Qrons Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Qrons's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Qrons's accounts receivable are only considered to be worth 75% of book value:

Qrons's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.004	+	0.75 * 0	+	0.5 * 0	-	1.475
-	0	-	0)	/	13.6498
=	-0.11

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Qrons Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Qrons's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Qrons (QRON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101

Website

https://www.qrons.com

Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.

Executives

John N Bonfiglio	officer: Chief Operating Officer	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer	director, 10 percent owner, officer: CEO, CFO and Secretary	28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld	director, 10 percent owner, officer: President	153 HAGILBOA STREET, NIRIT L3 44805